Zoetis Inc. ZTS
NYSE · XNYS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $9.5B | $2.7B | — | $2.3B | $3.4B |
| 2024 | $9.3B | $2.5B | — | $2.3B | $4.8B |
| 2023 | $8.5B | $2.3B | — | $1.6B | $5.0B |
| 2022 | $8.1B | $2.1B | — | $1.3B | $4.4B |
| 2021 | $7.8B | $2.0B | — | $1.7B | $4.5B |
| 2020 | $6.7B | $1.6B | — | $1.7B | $3.8B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| MCCALLISTER MICHAEL B | director | 2026-06-10 | Gift | 1,209 | — |
| Stetter Mark | director | 2026-05-21 | Option exercise | 1,572 | — |
| PARENT LOUISE M | director | 2026-05-20 | Option exercise | 1,944 | — |
| PARENT LOUISE M | director | 2026-05-20 | Option exercise | 10,186 | — |
| DAMELIO FRANK A | director | 2026-05-13 | Buy | 6,650 | $75.39 |
| Bisaro Paul | director | 2026-05-13 | Buy | 2,000 | $75.88 |
| MCCALLISTER MICHAEL B | director | 2026-05-11 | Buy | 3,000 | $77.76 |
| Esch Kevin | Executive Vice President | 2026-04-30 | Option exercise | 259 | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0001555280 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.